Serotype Emergence and Genotype Distribution among Macrolide-Resistant Invasive Streptococcus Pneumoniae Isolates in the Postconjugate Vaccine (PCV-7) Era
- 1 February 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (2), 743-750
- https://doi.org/10.1128/aac.05122-11
Abstract
We conducted population-based surveillance for pneumococcal bacteremia within a 5-county region surrounding Philadelphia from October 2001 through September 2008, the period following introduction of the seven-valent pneumococcal conjugate vaccine. Erythromycin resistance increased from 14.7% in 2001-2002 to 20.3% in 2007-2008, while the resistance rate to penicillin (MIC, ≥2 μg/ml) decreased from 7.2% to 4.2% during the same period. The most predominant serotypes associated with erythromycin resistance in 2007-2008 included 19A (29.7%), 15A (29.2%), 6C (10.1%), 3 (5.6%), and 6A (4.5%). The molecular mechanisms for the increasing erythromycin resistance were mainly due to the growing presence of mef(A) negative erm (B) + and mef(A) + erm (B) + genotypes, which increased from 20.0% to 46.1% and from 1.8% to 19.1%, respectively, from 2001-2002 to 2007-2008. However, mef(A) -mediated erythromycin resistance decreased from 72.7% in 2001-2002 to 34.8% in 2007-2008. Serotypes related to the erm (B) gene were 15A (45.6%), 19A (20.9%), 3 (10.1%), and 6B (6.3%); serotypes related to the mef(A) gene were 6A (18.6%), 19A (15.0%), 6C (9.3%), and 14(8.4%); serotypes associated with the presence of both erm (B) and mef(A) were 19A (81.5%), 15A (7.7%), and 19F (6.2%). Pulsed-field gel electrophoresis analysis demonstrated that erythromycin-resistant isolates within the 19A serotype were genetically diverse and related to several circulating international clones. In contrast, erythromycin-resistant isolates within the 15A serotype consisted of clonally identical or closely related isolates.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypesInternational Journal of Antimicrobial Agents, 2010
- Exposure to Children as a Risk Factor for Bacteremic Pneumococcal DiseaseJAMA Internal Medicine, 2010
- Increase in Pneumococcus Macrolide Resistance, United StatesEmerging Infectious Diseases, 2009
- Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6CThe Journal of Infectious Diseases, 2008
- Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004)International Journal of Antimicrobial Agents, 2008
- Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4Annals of Clinical Microbiology and Antimicrobials, 2008
- Pneumococcal Resistance to Macrolides, Lincosamides, Ketolides, and Streptogramin B Agents: Molecular Mechanisms and Resistance PhenotypesClinical Infectious Diseases, 2004
- Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 StudyAntimicrobial Agents and Chemotherapy, 2003
- The new pneumococcal vaccineClinical Microbiology & Infection, 2002
- The Emergence ofStreptococcus pneumoniaeResistant to Macrolide Antimicrobial Agents: A 6‐Year Population‐Based AssessmentThe Journal of Infectious Diseases, 2000